BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-1081. [PMID: 20335583 DOI: 10.1056/nejmoa0907893] [Cited by in Crossref: 731] [Cited by in F6Publishing: 259] [Article Influence: 60.9] [Reference Citation Analysis]
Number Citing Articles
1 Ramírez-polo A, Márquez-guillén E, González-aguirre AJ, Casanova-sánchez IE, Chávez-ruiz R, Carrillo-maravilla E, López-méndez E. Persistent hepatic encephalopathy secondary to portosystemic shunt occluded with Amplatzer device. Annals of Hepatology 2014;13:456-60. [DOI: 10.1016/s1665-2681(19)30854-3] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Zhang YB, Liu ZK, Chen LM, Yuan YS, Ji ZW, Li JG. Assessment of cognitive function of patients after resolution of overt hepatic encephalopathy with ice cap participated treatment. Shijie Huaren Xiaohua Zazhi 2014; 22(5): 679-684 [DOI: 10.11569/wcjd.v22.i5.679] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 2016; 22(29): 6638-6651 [PMID: 27547007 DOI: 10.3748/wjg.v22.i29.6638] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
4 Bajaj JS. Introduction and setting the scene: New nomenclature of hepatic encephalopathy and American Association for the Study of Liver Diseases/European Association for the Study of the Liver guidelines. Clin Liver Dis (Hoboken) 2017;9:48-51. [PMID: 30992956 DOI: 10.1002/cld.610] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Neff GW, Kemmer N, Duncan C, Alsina A. Update on the management of cirrhosis - focus on cost-effective preventative strategies. Clinicoecon Outcomes Res 2013;5:143-52. [PMID: 23626470 DOI: 10.2147/CEOR.S30675] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
6 Pradere JP, Dapito DH, Schwabe RF. The Yin and Yang of Toll-like receptors in cancer. Oncogene. 2014;33:3485-3495. [PMID: 23934186 DOI: 10.1038/onc.2013.302] [Cited by in Crossref: 179] [Cited by in F6Publishing: 163] [Article Influence: 19.9] [Reference Citation Analysis]
7 Wang Z, Chu P, Wang W. Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy. Drug Des Devel Ther. 2019;13:1-11. [PMID: 30587923 DOI: 10.2147/dddt.s172324] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
8 Freedland KE, Mohr DC, Davidson KW, Schwartz JE. Usual and unusual care: existing practice control groups in randomized controlled trials of behavioral interventions. Psychosom Med 2011;73:323-35. [PMID: 21536837 DOI: 10.1097/PSY.0b013e318218e1fb] [Cited by in Crossref: 173] [Cited by in F6Publishing: 97] [Article Influence: 15.7] [Reference Citation Analysis]
9 Rockey DC, Vierling JM, Mantry P, Ghabril M, Brown RS, Alexeeva O, Zupanets IA, Grinevich V, Baranovsky A, Dudar L, Fadieienko G, Kharchenko N, Klaryts'ka I, Morozov V, Grewal P, McCashland T, Reddy KG, Reddy KR, Syplyviy V, Bass NM, Dickinson K, Norris C, Coakley D, Mokhtarani M, Scharschmidt BF; HALT-HE Study Group. Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology. 2014;59:1073-1083. [PMID: 23847109 DOI: 10.1002/hep.26611] [Cited by in Crossref: 98] [Cited by in F6Publishing: 75] [Article Influence: 12.3] [Reference Citation Analysis]
10 Fukui H. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia. World J Hepatol 2015; 7(3): 425-442 [PMID: 25848468 DOI: 10.4254/wjh.v7.i3.425] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 14.1] [Reference Citation Analysis]
11 Katsounas A, Canbay A. Intensive Care Therapy for Patients with Advanced Liver Diseases. Visc Med 2018;34:283-9. [PMID: 30345286 DOI: 10.1159/000492088] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
12 Li H, Xiang Y, Zhu Z, Wang W, Jiang Z, Zhao M, Cheng S, Pan F, Liu D, Ho RCM, Ho CSH. Rifaximin-mediated gut microbiota regulation modulates the function of microglia and protects against CUMS-induced depression-like behaviors in adolescent rat. J Neuroinflammation 2021;18:254. [PMID: 34736493 DOI: 10.1186/s12974-021-02303-y] [Reference Citation Analysis]
13 Hudson M, Radwan A, Di Maggio P, Cipelli R, Ryder SD, Dillon JF, Cash WJ, Przemioslo RT, Wright M, Shawcross DL, Jalan R, Saksena S, Allison M, Richardson P, Farrington E, Aspinall RJ. The impact of rifaximin-α on the hospital resource use associated with the management of patients with hepatic encephalopathy: a retrospective observational study (IMPRESS). Frontline Gastroenterol 2017;8:243-51. [PMID: 29067149 DOI: 10.1136/flgastro-2016-100792] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
14 Coronel-castillo C, Contreras-carmona J, Frati-munari A, Uribe M, Méndez-sánchez N. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy. Revista de Gastroenterología de México (English Edition) 2020;85:56-68. [DOI: 10.1016/j.rgmxen.2019.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Cudalbu C, Taylor-Robinson SD. Brain Edema in Chronic Hepatic Encephalopathy. J Clin Exp Hepatol 2019;9:362-82. [PMID: 31360029 DOI: 10.1016/j.jceh.2019.02.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
16 Swaminathan M, Ellul MA, Cross TJ. Hepatic encephalopathy: current challenges and future prospects. Hepat Med. 2018;10:1-11. [PMID: 29606895 DOI: 10.2147/hmer.s118964] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 5.8] [Reference Citation Analysis]
17 Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, Noble NA, White MB, Fisher A, Sikaroodi M, Rangwala H, Gillevet PM. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One. 2013;8:e60042. [PMID: 23565181 DOI: 10.1371/journal.pone.0060042] [Cited by in Crossref: 227] [Cited by in F6Publishing: 220] [Article Influence: 25.2] [Reference Citation Analysis]
18 Amodio P. Current Diagnosis and Classification of Hepatic Encephalopathy. J Clin Exp Hepatol 2018;8:432-7. [PMID: 30564001 DOI: 10.1016/j.jceh.2018.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
19 Elwir S, Rahimi RS. Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options. J Clin Transl Hepatol. 2017;5:142-151. [PMID: 28660152 DOI: 10.14218/jcth.2016.00069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
20 Butterworth RF, Kircheis G, Hilger N, McPhail MJW. Efficacy of l-Ornithine l-Aspartate for the Treatment of Hepatic Encephalopathy and Hyperammonemia in Cirrhosis: Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Exp Hepatol. 2018;8:301-313. [PMID: 30302048 DOI: 10.1016/j.jceh.2018.05.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
21 Stallinger S, Eller N, Högenauer C. Non-interventional study evaluating efficacy and tolerability of rifaximin for treatment of uncomplicated diverticular disease. Wien Klin Wochenschr 2014;126:9-14. [PMID: 24240607 DOI: 10.1007/s00508-013-0447-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
22 Major G, Bradshaw L, Boota N, Sprange K, Diggle M, Montgomery A, Jawhari A, Spiller RC; RAPID Collaboration Group. Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial. Gut 2019;68:1224-31. [PMID: 30254135 DOI: 10.1136/gutjnl-2018-316794] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
23 Lamb C, Reddy AV. Rifaximin may have a dramatic effect on hepatic encephalopathy. Clin Med (Lond) 2012;12:489-90. [PMID: 23101155 DOI: 10.7861/clinmedicine.12-5-489] [Reference Citation Analysis]
24 Mangas-Losada A, García-García R, Leone P, Ballester MP, Cabrera-Pastor A, Urios A, Gallego JJ, Martínez-Pretel JJ, Giménez-Garzó C, Revert F, Escudero-García D, Tosca J, Ríos MP, Montón C, Durbán L, Aparicio L, Montoliu C, Felipo V. Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy. J Transl Med 2019;17:293. [PMID: 31462286 DOI: 10.1186/s12967-019-2046-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
25 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications. Clin Mol Hepatol 2020;26:83-127. [PMID: 31918536 DOI: 10.3350/cmh.2019.0010n] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
26 Singh SP, Wadhawan M, Acharya SK, Bopanna S, Madan K, Sahoo MK, Bhat N, Misra SP, Duseja A, Mukund A, Anand AC, Goel A, Satyaprakash BS, Varghese J, Panigrahi MK, Tandan M, Mohapatra MK, Puri P, Rathi PM, Wadhwa RP, Taneja S, Thomas V, Bhatia V; Indian Society of Gastroenterology Task Force on Upper Gastrointestinal Bleeding. Management of portal hypertensive upper gastrointestinal bleeding: Report of the Coorg Consensus workshop of the Indian Society of Gastroenterology Task Force on Upper Gastrointestinal Bleeding. Indian J Gastroenterol 2021. [PMID: 34890020 DOI: 10.1007/s12664-021-01169-5] [Reference Citation Analysis]
27 Feuerstadt P, Hong SJ, Brandt LJ. Chronic Rifaximin Use in Cirrhotic Patients Is Associated with Decreased Rate of C. difficile Infection. Dig Dis Sci 2020;65:632-8. [DOI: 10.1007/s10620-019-05804-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
28 Waghray N, Waghray A, Mullen K. Treatment options for covert hepatic encephalopathy. Curr Treat Options Gastroenterol. 2014;12:229-241. [PMID: 24623592 DOI: 10.1007/s11938-014-0014-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Ridola L, Faccioli J, Nardelli S, Gioia S, Riggio O. Hepatic Encephalopathy: Diagnosis and Management. J Transl Int Med 2020;8:210-9. [PMID: 33511048 DOI: 10.2478/jtim-2020-0034] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Tatsumi R, Suii H, Yamaguchi M, Arakawa T, Nakajima T, Kuwata Y, Toyota J, Hige S. Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis. Intern Med 2021;60:1501-7. [PMID: 33361677 DOI: 10.2169/internalmedicine.6039-20] [Reference Citation Analysis]
31 Park BJ, Lee YJ, Lee HR. Chronic liver inflammation: Clinical implications beyond alcoholic liver disease. World J Gastroenterol 2014; 20(9): 2168-2175 [PMID: 24605015 DOI: 10.3748/wjg.v20.i9.2168] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
32 Yu X, Jin Y, Zhou W, Xiao T, Wu Z, Su J, Gao H, Shen P, Zheng B, Luo Q, Li L, Xiao Y. Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Front Cell Infect Microbiol 2022;11:761192. [DOI: 10.3389/fcimb.2021.761192] [Reference Citation Analysis]
33 Babineaux MJ, Anand BS. General aspects of the treatment of alcoholic hepatitis. World J Hepatol 2011; 3(5): 125-129 [PMID: 21731906 DOI: 10.4254/wjh.v3.i5.125] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
34 Atluri DK, Prakash R, Mullen KD. Pathogenesis, diagnosis, and treatment of hepatic encephalopathy. J Clin Exp Hepatol. 2011;1:77-86. [PMID: 25755319 DOI: 10.1016/s0973-6883(11)60126-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
35 Riggio O, Ridola L, Pasquale C. Hepatic encephalopathy therapy: An overview. World J Gastrointest Pharmacol Ther 2010; 1(2): 54-63 [PMID: 21577297 DOI: 10.4292/wjgpt.v1.i2.54] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
36 Rathi S, Fagan A, Wade JB, Chopra M, White MB, Ganapathy D, Acharya C, Dhiman RK, Bajaj JS. Patient Acceptance of Lactulose Varies Between Indian and American Cohorts: Implications for Comparing and Designing Global Hepatic Encephalopathy Trials. J Clin Exp Hepatol 2018;8:109-15. [PMID: 29892171 DOI: 10.1016/j.jceh.2017.11.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
37 Felipo V. Hepatic encephalopathy: effects of liver failure on brain function. Nat Rev Neurosci. 2013;14:851-858. [PMID: 24149188 DOI: 10.1038/nrn3587] [Cited by in Crossref: 196] [Cited by in F6Publishing: 186] [Article Influence: 21.8] [Reference Citation Analysis]
38 Betrapally NS, Gillevet PM, Bajaj JS. Gut microbiome and liver disease. Transl Res. 2017;179:49-59. [PMID: 27477080 DOI: 10.1016/j.trsl.2016.07.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 7.2] [Reference Citation Analysis]
39 Kabeshova A, Ben Hariz S, Tsakeu E, Benamouzig R, Launois R. Cost-effectiveness analysis of rifaximin-α administration for the reduction of episodes of overt hepatic encephalopathy in recurrence compared with standard treatment in France. Therap Adv Gastroenterol 2016;9:473-82. [PMID: 27366216 DOI: 10.1177/1756283X16644249] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
40 Roggeri DP, Roggeri A. Economic impact of the use of rifaximin 550 mg twice daily for the treatment of overt hepatic encephalopathy in Italy. Hepat Med 2017;9:37-43. [PMID: 29026340 DOI: 10.2147/HMER.S146438] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
41 Sarangi AN, Goel A, Singh A, Sasi A, Aggarwal R. Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration. BMC Gastroenterol 2017;17:125. [PMID: 29179682 DOI: 10.1186/s12876-017-0683-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
42 Stremmel W, Schmidt KV, Schuhmann V, Kratzer F, Garbade SF, Langhans CD, Fricker G, Okun JG. Blood Trimethylamine-N-Oxide Originates from Microbiota Mediated Breakdown of Phosphatidylcholine and Absorption from Small Intestine. PLoS One 2017;12:e0170742. [PMID: 28129384 DOI: 10.1371/journal.pone.0170742] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
43 Montgomery JY, Bajaj JS. Advances in the evaluation and management of minimal hepatic encephalopathy. Curr Gastroenterol Rep. 2011;13:26-33. [PMID: 20924726 DOI: 10.1007/s11894-010-0150-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
44 Lee GH. Hepatic encephalopathy in acute-on-chronic liver failure. Hepatol Int. 2015;9:520-526. [PMID: 26016460 DOI: 10.1007/s12072-015-9626-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
45 Flamm SL, Mullen KD, Heimanson Z, Sanyal AJ. Rifaximin has the potential to prevent complications of cirrhosis. Therap Adv Gastroenterol. 2018;11:1756284818800307. [PMID: 30283499 DOI: 10.1177/1756284818800307] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
46 Kim SE, Park JW, Kim HS, Jang MK, Suk KT, Kim DJ. The Role of Gut Dysbiosis in Acute-on-Chronic Liver Failure. Int J Mol Sci 2021;22:11680. [PMID: 34769109 DOI: 10.3390/ijms222111680] [Reference Citation Analysis]
47 Dery KJ, Kadono K, Hirao H, Górski A, Kupiec-Weglinski JW. Microbiota in organ transplantation: An immunological and therapeutic conundrum? Cell Immunol 2020;351:104080. [PMID: 32139071 DOI: 10.1016/j.cellimm.2020.104080] [Reference Citation Analysis]
48 Blandizzi C, Viscomi GC, Scarpignato C. Impact of crystal polymorphism on the systemic bioavailability of rifaximin, an antibiotic acting locally in the gastrointestinal tract, in healthy volunteers. Drug Des Devel Ther 2015;9:1-11. [PMID: 25565769 DOI: 10.2147/DDDT.S72572] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
49 Bruyneel M, Sersté T. Sleep disturbances in patients with liver cirrhosis: prevalence, impact, and management challenges. Nat Sci Sleep 2018;10:369-75. [PMID: 30464664 DOI: 10.2147/NSS.S186665] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.8] [Reference Citation Analysis]
50 Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Reference Citation Analysis]
51 Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. Int J Mol Sci. 2020;21:5254. [PMID: 32722100 DOI: 10.3390/ijms21155254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
52 Kc M, Olson APJ, Wang Q, Lim N. Unexpected clinical outcomes following the implementation of a standardised order set for hepatic encephalopathy. BMJ Open Gastroenterol 2021;8:e000621. [PMID: 33866310 DOI: 10.1136/bmjgast-2021-000621] [Reference Citation Analysis]
53 Shalimar, Acharya SK. Management in acute liver failure. J Clin Exp Hepatol 2015;5:S104-15. [PMID: 26041950 DOI: 10.1016/j.jceh.2014.11.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
54 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
55 Benten D, Schulze zur Wiesch J, Sydow K, Koops A, Buggisch P, Böger RH, Gaydos CA, Won H, Franco V, Lohse AW, Ray SC, Balagopal A. The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS). BMC Gastroenterol 2011;11:107. [PMID: 21978390 DOI: 10.1186/1471-230X-11-107] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
56 Sauerbruch T, Hennenberg M, Trebicka J, Beuers U. Bile Acids, Liver Cirrhosis, and Extrahepatic Vascular Dysfunction. Front Physiol 2021;12:718783. [PMID: 34393832 DOI: 10.3389/fphys.2021.718783] [Reference Citation Analysis]
57 Chavarria L, Cordoba J. Encephalopathy and liver transplantation. Metab Brain Dis 2013;28:285-92. [PMID: 23154925 DOI: 10.1007/s11011-012-9350-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
58 Kim TY, Kim DJ. Acute-on-chronic liver failure. Clin Mol Hepatol. 2013;19:349-359. [PMID: 24459638 DOI: 10.3350/cmh. 2013.19.4.349] [Reference Citation Analysis]
59 Macnaughtan J, Jalan R. Clinical and Pathophysiological Consequences of Alterations in the Microbiome in Cirrhosis. American Journal of Gastroenterology 2015;110:1399-410. [DOI: 10.1038/ajg.2015.313] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
60 Suraweera DB, Weeratunga AN, Hu RW, Pandol SJ, Hu R. Alcoholic hepatitis: The pivotal role of Kupffer cells. World J Gastrointest Pathophysiol 2015; 6(4): 90-98 [PMID: 26600966 DOI: 10.4291/wjgp.v6.i4.90] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
61 Schulz C, Schütte K, Kropf S, Schmitt FC, Vasapolli R, Kliegis LM, Riegger A, Malfertheiner P. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial. Trials. 2016;17:111. [PMID: 26926775 DOI: 10.1186/s13063-016-1205-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
62 Saji N, Murotani K, Hisada T, Kunihiro T, Tsuduki T, Sugimoto T, Kimura A, Niida S, Toba K, Sakurai T. Relationship between dementia and gut microbiome-associated metabolites: a cross-sectional study in Japan. Sci Rep 2020;10:8088. [PMID: 32424166 DOI: 10.1038/s41598-020-65196-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
63 Teh KB, Loo JH, Tam YC, Wong YJ. Efficacy and safety of albumin infusion for overt hepatic encephalopathy: A systematic review and meta-analysis. Dig Liver Dis 2021;53:817-23. [PMID: 34011479 DOI: 10.1016/j.dld.2021.04.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Egan K, Dillon A, Dunne E, Kevane B, Galvin Z, Maguire P, Kenny D, Stewart S, Ainle FN. Increased soluble GPVI levels in cirrhosis: evidence for early in vivo platelet activation. J Thromb Thrombolysis 2017;43:54-9. [PMID: 27416950 DOI: 10.1007/s11239-016-1401-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
65 Stinton LM, Jayakumar S. Minimal hepatic encephalopathy. Can J Gastroenterol 2013;27:572-4. [PMID: 24106728 DOI: 10.1155/2013/547670] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.3] [Reference Citation Analysis]
66 Grattagliano I, Ubaldi E, Bonfrate L, Portincasa P. Management of liver cirrhosis between primary care and specialists. World J Gastroenterol 2011; 17(18): 2273-2282 [PMID: 21633593 DOI: 10.3748/wjg.v17.i18.2273] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
67 Tranah TH, Paolino A, Shawcross DL. Pathophysiological mechanisms of hepatic encephalopathy. Clin Liver Dis (Hoboken) 2015;5:59-63. [PMID: 31040951 DOI: 10.1002/cld.445] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
68 Jaurigue MM, Cappell MS. Therapy for alcoholic liver disease. World J Gastroenterol 2014; 20(9): 2143-2158 [PMID: 24605013 DOI: 10.3748/wjg.v20.i9.2143] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 33] [Article Influence: 4.9] [Reference Citation Analysis]
69 Sepehrinezhad A, Shahbazi A, Sahab Negah S, Joghataei MT, Larsen FS. Drug-induced-acute liver failure: A critical appraisal of the thioacetamide model for the study of hepatic encephalopathy. Toxicol Rep 2021;8:962-70. [PMID: 34026559 DOI: 10.1016/j.toxrep.2021.04.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Ridola L, Cardinale V, Riggio O. The burden of minimal hepatic encephalopathy: From diagnosis to therapeutic strategies. Ann Gastroenterol. 2018;31:151-164. [PMID: 29507462 DOI: 10.20524/aog.2018.0232] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
71 Roggeri DP, Roggeri A, Rossi E, Cinconze E, Gasbarrini A, Monici Preti P, De Rosa M. Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs. Hepat Med. 2015;7:37-42. [PMID: 26203290 DOI: 10.2147/hmer.s87594] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
72 Rowley MW, Choi M, Chen S, Hirsch K, Seetharam AB. Race and Gradient Difference Are Associated with Increased Risk of Hepatic Encephalopathy Hospital Admission After Transjugular Intrahepatic Portosystemic Shunt Placement. J Clin Exp Hepatol 2018;8:256-61. [PMID: 30302042 DOI: 10.1016/j.jceh.2017.12.003] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
73 Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology. 2015;148:30-36. [PMID: 25447847 DOI: 10.1053/j.gastro.2014.10.042] [Cited by in Crossref: 314] [Cited by in F6Publishing: 303] [Article Influence: 39.3] [Reference Citation Analysis]
74 Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK, Stravitz RT, Luketic V, Fuchs M, White MB, Bell DE, Gilles H, Morton K, Noble N, Puri P, Sanyal AJ. The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol. 2011;106:1646-1653. [PMID: 21556040 DOI: 10.1038/ajg.2011.157] [Cited by in Crossref: 201] [Cited by in F6Publishing: 173] [Article Influence: 18.3] [Reference Citation Analysis]
75 Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY. Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis. Gastroenterol Res Pract. 2013;2013:236963. [PMID: 23653636 DOI: 10.1155/2013/236963] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
76 Allampati SK, Mullen KD. Understanding the impact of neurologic complications in patients with cirrhosis. SAGE Open Med. 2019;7:2050312119832090. [PMID: 30834114 DOI: 10.1177/2050312119832090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
77 Kockerling D, Nathwani R, Forlano R, Manousou P, Mullish BH, Dhar A. Current and future pharmacological therapies for managing cirrhosis and its complications. World J Gastroenterol 2019; 25(8): 888-908 [PMID: 30833797 DOI: 10.3748/wjg.v25.i8.888] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
78 Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: Role of oxidative metabolism. World J Gastroenterol 2014; 20(47): 17756-17772 [PMID: 25548474 DOI: 10.3748/wjg.v20.i47.17756] [Cited by in CrossRef: 184] [Cited by in F6Publishing: 166] [Article Influence: 23.0] [Reference Citation Analysis]
79 Neff G, Zachry W III. Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin. Pharmacoeconomics 2018;36:809-22. [PMID: 29651649 DOI: 10.1007/s40273-018-0641-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 6.7] [Reference Citation Analysis]
80 Lin ZN, Zuo YQ, Hu P. Association of Proton Pump Inhibitor Therapy with Hepatic Encephalopathy in Hepatitis B Virus-related Acute-on-Chronic Liver Failure. Hepat Mon 2014;14:e16258. [PMID: 24748895 DOI: 10.5812/hepatmon.16258] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
81 Aldridge DR, Tranah EJ, Shawcross DL. Pathogenesis of hepatic encephalopathy: role of ammonia and systemic inflammation. J Clin Exp Hepatol. 2015;5:S7-S20. [PMID: 26041962 DOI: 10.1016/j.jceh.2014.06.004] [Cited by in Crossref: 108] [Cited by in F6Publishing: 90] [Article Influence: 13.5] [Reference Citation Analysis]
82 Sung H, Kim SW, Hong M, Suk KT. Microbiota-based treatments in alcoholic liver disease. World J Gastroenterol 2016; 22(29): 6673-6682 [PMID: 27547010 DOI: 10.3748/wjg.v22.i29.6673] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
83 Dhokia VD, Madhavan D, Austin A, Morris CG. Novel use of Cytosorb™ haemadsorption to provide biochemical control in liver impairment. J Intensive Care Soc 2019;20:174-81. [PMID: 31037112 DOI: 10.1177/1751143718772789] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
84 Trivedi HD, Tapper EB. Interventions to improve physical function and prevent adverse events in cirrhosis. Gastroenterol Rep (Oxf) 2018;6:13-20. [PMID: 29479438 DOI: 10.1093/gastro/gox042] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
85 Pandrea I, Xu C, Stock JL, Frank DN, Ma D, Policicchio BB, He T, Kristoff J, Cornell E, Haret-Richter GS, Trichel A, Ribeiro RM, Tracy R, Wilson C, Landay AL, Apetrei C. Antibiotic and Antiinflammatory Therapy Transiently Reduces Inflammation and Hypercoagulation in Acutely SIV-Infected Pigtailed Macaques. PLoS Pathog 2016;12:e1005384. [PMID: 26764484 DOI: 10.1371/journal.ppat.1005384] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
86 Ridola L, Riggio O, Gioia S, Faccioli J, Nardelli S. Clinical management of type C hepatic encephalopathy. United European Gastroenterol J 2020;8:536-43. [PMID: 32213035 DOI: 10.1177/2050640620909675] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
87 Nguyen HH, Swain MG, Wong P, Congly SE. Canadian regulations and legal ramifications for hepatic encephalopathy: a descriptive analysis. CMAJ Open 2018;6:E575-9. [PMID: 30510040 DOI: 10.9778/cmajo.20180024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Hirschfield GM, Dyson JK, Alexander GJM, Chapman MH, Collier J, Hübscher S, Patanwala I, Pereira SP, Thain C, Thorburn D, Tiniakos D, Walmsley M, Webster G, Jones DEJ. The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut 2018;67:1568-94. [PMID: 29593060 DOI: 10.1136/gutjnl-2017-315259] [Cited by in Crossref: 93] [Cited by in F6Publishing: 69] [Article Influence: 23.3] [Reference Citation Analysis]
89 Wong F. Clinical Consequences of Infection in Cirrhosis: Organ Failures and Acute-on-Chronic Liver Failure. Clin Liver Dis (Hoboken) 2019;14:92-7. [PMID: 31632657 DOI: 10.1002/cld.813] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
90 Dong TS, Jacobs JP, Hussain SK. Microbial Profiles of Cirrhosis in the Human Small Intestine. Curr Gastroenterol Rep 2019;21:50. [PMID: 31444636 DOI: 10.1007/s11894-019-0717-2] [Reference Citation Analysis]
91 Madsen BS, Trebicka J, Thiele M, Israelsen M, Arumugan M, Havelund T, Krag A. Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial. Trials. 2018;19:143. [PMID: 29482588 DOI: 10.1186/s13063-018-2523-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
92 Òdena G, Miquel M, Serafín A, Galan A, Morillas R, Planas R, Bartolí R. Rifaximin, but not growth factor 1, reduces brain edema in cirrhotic rats. World J Gastroenterol 2012; 18(17): 2084-2091 [PMID: 22563196 DOI: 10.3748/wjg.v18.i17.2084] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
93 Ridola L, Nardelli S, Gioia S, Riggio O. How to design a multicenter clinical trial in Hepatic Encephalopathy. JCEH 2018 in press. . [PMID: 30765947 DOI: 10.1016/j.jceh.2018.02.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
94 Kong X, Luo S, Wang YF, Yang GF, Lu GM, Zhang LJ. [18F]PBR146 and [18F]DPA-714 in vivo Imaging of Neuroinflammation in Chronic Hepatic Encephalopathy Rats. Front Neurosci 2021;15:678144. [PMID: 34483820 DOI: 10.3389/fnins.2021.678144] [Reference Citation Analysis]
95 Kortt NC, Santhakumar C, Davis RJ, Strasser SI, McCaughan GW, Liu K, Majumdar A. Prevalence and outcomes of Clostridioides difficile infection in liver transplant recipients. Transpl Infect Dis 2021;:e13758. [PMID: 34762768 DOI: 10.1111/tid.13758] [Reference Citation Analysis]
96 Hudson M, Schuchmann M. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence. Eur J Gastroenterol Hepatol. 2019;31:434-450. [PMID: 30444745 DOI: 10.1097/meg.0000000000001311] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 7.3] [Reference Citation Analysis]
97 Strebel H, Haller B, Sohn M, Schepp W, Gundling F. Role of Brain Biomarkers S-100-Beta and Neuron-Specific Enolase for Detection and Follow-Up of Hepatic Encephalopathy in Cirrhosis before, during and after Treatment with L-Ornithine-L-Aspartate. GE Port J Gastroenterol 2020;27:391-403. [PMID: 33251288 DOI: 10.1159/000507225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Jørgensen SF, Macpherson ME, Bjørnetrø T, Holm K, Kummen M, Rashidi A, Michelsen AE, Lekva T, Halvorsen B, Trøseid M, Mollnes TE, Berge RK, Yndestad A, Ueland T, Karlsen TH, Aukrust P, Hov JR, Fevang B. Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency. Sci Rep 2019;9:167. [PMID: 30655568 DOI: 10.1038/s41598-018-35367-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
99 Pose E, Solà E, Lozano JJ, Juanola A, Sidorova J, Zaccherini G, de Wit K, Uschner F, Tonon M, Kazankov K, Jiménez C, Campion D, Napoleone L, Ma AT, Carol M, Morales-Ruiz M, Alessandria C, Beuers U, Caraceni P, Francoz C, Durand F, Mookerjee RP, Trebicka J, Vargas V, Piano S, Watson H, Abraldes JG, Kamath PS, Davis MM, Ginès P; investigators of the LIVERHOPE Consortium. Treatment With Simvastatin and Rifaximin Restores the Plasma Metabolomic Profile in Patients With Decompensated Cirrhosis. Hepatol Commun 2021. [PMID: 34964311 DOI: 10.1002/hep4.1881] [Reference Citation Analysis]
100 Kimer N, Gudmann NS, Pedersen JS, Møller S, Nielsen MJ, Leeming DJ, Karsdal MA, Møller HJ, Bendtsen F, Grønbæk H. No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neoepitope collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. PLoS One 2018;13:e0203200. [PMID: 30183743 DOI: 10.1371/journal.pone.0203200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
101 Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs conventional oral therapy for hepatic encephalopathy: A meta-analysis. World J Gastroenterol 2012; 18(8): 767-777 [PMID: 22371636 DOI: 10.3748/wjg.v18.i8.767] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
102 Yang J, Zhou SC, Zhang JL, Yang YX. Clinical effects of ornithine aspartate combined with rifaximin in treatment of acute hepatic encephalopathy. Shijie Huaren Xiaohua Zazhi 2016; 24(3): 415-419 [DOI: 10.11569/wcjd.v24.i3.415] [Reference Citation Analysis]
103 Cheng J, Chen Y, Cao W, Zuo G. Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis. Medicine (Baltimore) 2021;100:e28232. [PMID: 34941089 DOI: 10.1097/MD.0000000000028232] [Reference Citation Analysis]
104 Tranah TH, Shawcross DL. The rise and fall and rise again of ammonia as a therapeutic target in hepatic encephalopathy. Hepatology 2022. [PMID: 34995377 DOI: 10.1002/hep.32319] [Reference Citation Analysis]
105 Zhu Q, Zou L, Jagavelu K, Simonetto DA, Huebert RC, Jiang ZD, DuPont HL, Shah VH. Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice. J Hepatol. 2012;56:893-899. [PMID: 22173161 DOI: 10.1016/j.jhep.2011.11.013] [Cited by in Crossref: 87] [Cited by in F6Publishing: 85] [Article Influence: 7.9] [Reference Citation Analysis]
106 Salman T, Elsabaawy M, Omar M, Afify M, Elezawy H, Ghanem S, Abdelraouf O, Rewisha E, Shebl N. Evaluation of different diagnostic modalities of minimal hepatic encephalopathy in cirrhotic patients: case-control study. Clin Exp Hepatol 2021;7:312-9. [PMID: 34712834 DOI: 10.5114/ceh.2021.109292] [Reference Citation Analysis]
107 Collins P, Ayres L, Valliani T. Drug therapies in liver disease. Clin Med (Lond) 2013;13:585-91. [PMID: 24298107 DOI: 10.7861/clinmedicine.13-6-585] [Reference Citation Analysis]
108 Purohit T, Cappell MS. Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol 2015; 7(7): 926-941 [PMID: 25954476 DOI: 10.4254/wjh.v7.i7.926] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 6.3] [Reference Citation Analysis]
109 Kakiyama G, Pandak WM, Gillevet PM, Hylemon PB, Heuman DM, Daita K, Takei H, Muto A, Nittono H, Ridlon JM, White MB, Noble NA, Monteith P, Fuchs M, Thacker LR, Sikaroodi M, Bajaj JS. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. J Hepatol 2013;58:949-55. [PMID: 23333527 DOI: 10.1016/j.jhep.2013.01.003] [Cited by in Crossref: 359] [Cited by in F6Publishing: 357] [Article Influence: 39.9] [Reference Citation Analysis]
110 Konturek PC, Harsch IA, Konturek K, Schink M, Konturek T, Neurath MF, Zopf Y. Gut⁻Liver Axis: How Do Gut Bacteria Influence the Liver? Med Sci (Basel) 2018;6:E79. [PMID: 30227645 DOI: 10.3390/medsci6030079] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 8.3] [Reference Citation Analysis]
111 Bleibel W, Al-Osaimi AM. Hepatic encephalopathy. Saudi J Gastroenterol. 2012;18:301-309. [PMID: 23006457 DOI: 10.4103/1319-3767.101123] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
112 Yan K, Garcia-Tsao G. Novel prevention strategies for bacterial infections in cirrhosis. Expert Opin Pharmacother. 2016;17:689-701. [PMID: 26799197 DOI: 10.1517/14656566.2016.1145663] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
113 Perumalswami PV, Schiano TD. The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci 2011;56:1266-81. [PMID: 21416246 DOI: 10.1007/s10620-011-1619-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
114 Liu A, Yoo ER, Siddique O, Perumpail RB, Cholankeril G, Ahmed A. Hepatic encephalopathy: what the multidisciplinary team can do. J Multidiscip Healthc. 2017;10:113-119. [PMID: 28392702 DOI: 10.2147/jmdh.s118963] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
115 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
116 Bajaj JS, O'Leary JG, Tandon P, Wong F, Kamath PS, Biggins SW, Garcia-Tsao G, Lai J, Fallon MB, Thuluvath PJ, Vargas HE, Maliakkal B, Subramanian RM, Thacker LR, Reddy KR. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort. Aliment Pharmacol Ther 2019;49:1518-27. [PMID: 31032966 DOI: 10.1111/apt.15265] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
117 Ferro JM, Viana P, Santos P. Management of Neurologic Manifestations in Patients with Liver Disease. Curr Treat Options Neurol 2016;18:37. [PMID: 27314429 DOI: 10.1007/s11940-016-0419-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
118 Reuter B, Walter K, Bissonnette J, Leise MD, Lai J, Tandon P, Kamath PS, Biggins SW, Rose CF, Wade JB, Bajaj JS. Assessment of the spectrum of hepatic encephalopathy: A multicenter study. Liver Transpl 2018;24:587-94. [PMID: 29457869 DOI: 10.1002/lt.25032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
119 Ponziani FR, Zocco MA, D’Aversa F, Pompili M, Gasbarrini A. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol 2017; 23(25): 4491-4499 [PMID: 28740337 DOI: 10.3748/wjg.v23.i25.4491] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 44] [Article Influence: 11.4] [Reference Citation Analysis]
120 Chautant F, Guillaume M, Robic MA, Cadranel JF, Peron JM, Lison H, Cool C, Bureau C, Duhalde V. Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy. World J Hepatol 2020; 12(1): 10-20 [PMID: 31984117 DOI: 10.4254/wjh.v12.i1.10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
121 Bai Z, Guo X, Tacke F, Li Y, Li H, Qi X. Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization. Therap Adv Gastroenterol 2019;12:1756284819881302. [PMID: 31636711 DOI: 10.1177/1756284819881302] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
122 Butterworth RF. The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nat Rev Gastroenterol Hepatol 2013;10:522-8. [PMID: 23817325 DOI: 10.1038/nrgastro.2013.99] [Cited by in Crossref: 101] [Cited by in F6Publishing: 95] [Article Influence: 11.2] [Reference Citation Analysis]
123 Sohal A, Green V, Sandhu S, Roytman M. Identifying areas of improvement in nursing knowledge regarding hepatic encephalopathy management. J Community Hosp Intern Med Perspect 2021;11:722-6. [PMID: 34567473 DOI: 10.1080/20009666.2021.1954784] [Reference Citation Analysis]
124 Nabi E, Bajaj JS. Useful tests for hepatic encephalopathy in clinical practice. Curr Gastroenterol Rep. 2014;16:362. [PMID: 24357348 DOI: 10.1007/s11894-013-0362-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
125 Zhan T, Stremmel W. The diagnosis and treatment of minimal hepatic encephalopathy. Dtsch Arztebl Int. 2012;109:180-187. [PMID: 22470407 DOI: 10.3238/arztebl.2012.0180] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
126 Poh Z, Chang PE. A current review of the diagnostic and treatment strategies of hepatic encephalopathy. Int J Hepatol. 2012;2012:480309. [PMID: 23133760 DOI: 10.1155/2012/480309] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
127 Sharma P, Sharma BC. Management Patterns of Hepatic Encephalopathy: A Nationwide Survey in India. J Clin Exp Hepatol 2015;5:199-203. [PMID: 26628837 DOI: 10.1016/j.jceh.2015.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
128 Zullo A, Hassan C, Ridola L, Lorenzetti R, Campo SM, Riggio O. Rifaximin therapy and hepatic encephalopathy: Pros and cons. World J Gastrointest Pharmacol Ther 2012; 3(4): 62-67 [PMID: 22966484 DOI: 10.4292/wjgpt.v3.i4.62] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
129 Engelmann C, Adebayo D, Oria M, De Chiara F, Novelli S, Habtesion A, Davies N, Andreola F, Jalan R. Recombinant Alkaline Phosphatase Prevents Acute on Chronic Liver Failure. Sci Rep 2020;10:389. [PMID: 31942020 DOI: 10.1038/s41598-019-57284-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
130 Chang C, Huang CH, Tseng HJ, Yang FC, Chien RN. Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan. J Pers Med 2021;11:478. [PMID: 34071787 DOI: 10.3390/jpm11060478] [Reference Citation Analysis]
131 Anand G, Zarrinpar A, Loomba R. Targeting Dysbiosis for the Treatment of Liver Disease. Semin Liver Dis. 2016;36:37-47. [PMID: 26870931 DOI: 10.1055/s-0035-1571276] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
132 Tapper EB, Aberasturi D, Zhao Z, Hsu CY, Parikh ND. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther 2020;51:1397-405. [PMID: 32363684 DOI: 10.1111/apt.15749] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
133 Salam M, Matherly S, Farooq IS, Stravitz RT, Sterling RK, Sanyal AJ, Gibson DP, Wade JB, Thacker LR, Heuman DM, Fuchs M, Puri P, Luketic V, Bickston SJ, Bajaj JS. Modified-orientation log to assess hepatic encephalopathy. Aliment Pharmacol Ther 2012;35:913-20. [PMID: 22348593 DOI: 10.1111/j.1365-2036.2012.05038.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
134 Sauerbruch T, Appenrodt B, Schmitz V, Spengler U. The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis. Dtsch Arztebl Int 2013;110:126-32, I. [PMID: 23505400 DOI: 10.3238/arztebl.2013.0126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
135 Hsu DC, Sereti I, Ananworanich J. Serious Non-AIDS events: Immunopathogenesis and interventional strategies. AIDS Res Ther 2013;10:29. [PMID: 24330529 DOI: 10.1186/1742-6405-10-29] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 4.7] [Reference Citation Analysis]
136 Grover VP, Tognarelli JM, Massie N, Crossey MM, Cook NA, Taylor-Robinson SD. The why and wherefore of hepatic encephalopathy. Int J Gen Med 2015;8:381-90. [PMID: 26719720 DOI: 10.2147/IJGM.S86854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
137 Bajaj JS. Microbiome and complications of liver disease. Clin Liver Dis (Hoboken) 2015;5:96-9. [PMID: 31040960 DOI: 10.1002/cld.460] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
138 Labenz C, Kostev K, Galle PR, Wörns MA, Schattenberg JM. Prescription rates of common medications in patients with decompensated cirrhosis in Germany. Z Gastroenterol 2021. [PMID: 34820806 DOI: 10.1055/a-1676-4822] [Reference Citation Analysis]
139 Bednarsch J, Czigany Z, Loosen SH, Heij L, Ruckgaber L, Maes H, Krause JP, Reen M, Toteva B, Vosdellen T, Bruners P, Lang SA, Ulmer TF, Roderburg C, Luedde T, Neumann UP. Perioperative rifaximin is not associated with enhanced functional and volumetric recovery after major liver resection. Sci Rep 2021;11:17936. [PMID: 34504196 DOI: 10.1038/s41598-021-97442-w] [Reference Citation Analysis]
140 Kornerup LS, Gluud LL, Vilstrup H, Dam G. Update on the Therapeutic Management of Hepatic Encephalopathy. Curr Gastroenterol Rep. 2018;20:21. [PMID: 29644492 DOI: 10.1007/s11894-018-0627-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.8] [Reference Citation Analysis]
141 Yoon JH, Jun CH, Kim JH, Yoon EL, Kim BS, Song JE, Suk KT, Kim MY, Kang SH. Changing Trends in Liver Cirrhosis Etiology and Severity in Korea: the Increasing Impact of Alcohol. J Korean Med Sci 2021;36:e145. [PMID: 34060260 DOI: 10.3346/jkms.2021.36.e145] [Reference Citation Analysis]
142 Lim YL, Kim MY, Jang YO, Baik SK, Kwon SO. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study. Gut Liver 2017;11:702-10. [PMID: 28651304 DOI: 10.5009/gnl16478] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
143 Kim TY, Kim DJ. Acute-on-chronic liver failure. Clin Mol Hepatol. 2013;19:349-359. [PMID: 24459638 DOI: 10.3350/cmh. 2013.19.4.349] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
144 Macnaughtan J, Jalan R. Clinical and pathophysiological consequences of alterations in the microbiome in cirrhosis. Am J Gastroenterol. 2015;110:1399-1410; quiz 1411. [PMID: 26416191 DOI: 10.1038/ajg.2015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Losurdo G, Salvatore D'Abramo F, Indellicati G, Lillo C, Ierardi E, Di Leo A. The Influence of Small Intestinal Bacterial Overgrowth in Digestive and Extra-Intestinal Disorders. Int J Mol Sci 2020;21:E3531. [PMID: 32429454 DOI: 10.3390/ijms21103531] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
146 Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. Hepatology 2012;55:1164-71. [PMID: 22135042 DOI: 10.1002/hep.25507] [Cited by in Crossref: 85] [Cited by in F6Publishing: 73] [Article Influence: 8.5] [Reference Citation Analysis]
147 Shawcross DL, Dunk AA, Jalan R, Kircheis G, de Knegt RJ, Laleman W, Ramage JK, Wedemeyer H, Morgan IE; New Insights Steering Committee. How to diagnose and manage hepatic encephalopathy: a consensus statement on roles and responsibilities beyond the liver specialist. Eur J Gastroenterol Hepatol. 2016;28:146-152. [PMID: 26600154 DOI: 10.1097/meg.0000000000000529] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
148 Waghray A, Waghray N, Mullen K. Management of covert hepatic encephalopathy. J Clin Exp Hepatol 2015;5:S75-81. [PMID: 26041963 DOI: 10.1016/j.jceh.2014.02.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
149 Trebicka J, Bork P, Krag A, Arumugam M. Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. Nat Rev Gastroenterol Hepatol 2021;18:167-80. [PMID: 33257833 DOI: 10.1038/s41575-020-00376-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
150 Hernández-Gea V, Berbel C, Baiges A, García-Pagán JC. Acute variceal bleeding: risk stratification and management (including TIPS). Hepatol Int 2018;12:81-90. [PMID: 28634688 DOI: 10.1007/s12072-017-9804-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
151 Lutz P, Parcina M, Bekeredjian-Ding I, Hoerauf A, Strassburg CP, Spengler U. Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin. Infection. 2014;42:175-177. [PMID: 23526308 DOI: 10.1007/s15010-013-0449-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
152 Orman ES, Odena G, Bataller R. Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. J Gastroenterol Hepatol. 2013;28 Suppl 1:77-84. [PMID: 23855300 DOI: 10.1111/jgh.12030] [Cited by in Crossref: 144] [Cited by in F6Publishing: 138] [Article Influence: 18.0] [Reference Citation Analysis]
153 Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Vilstrup H. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis. 2013;28:221-225. [PMID: 23275147 DOI: 10.1007/s11011-012-9372-0] [Cited by in Crossref: 61] [Cited by in F6Publishing: 45] [Article Influence: 6.1] [Reference Citation Analysis]
154 Hong M, Han DH, Hong J, Kim DJ, Suk KT. Are Probiotics Effective in Targeting Alcoholic Liver Diseases? Probiotics Antimicrob Proteins 2019;11:335-47. [PMID: 29687200 DOI: 10.1007/s12602-018-9419-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
155 De Palma G, Collins SM, Bercik P. The microbiota-gut-brain axis in functional gastrointestinal disorders. Gut Microbes. 2014;5:419-429. [PMID: 24921926 DOI: 10.4161/gmic.29417] [Cited by in Crossref: 72] [Cited by in F6Publishing: 61] [Article Influence: 9.0] [Reference Citation Analysis]
156 Spahn S, Roessler D, Pompilia R, Gabernet G, Gladstone BP, Horger M, Biskup S, Feldhahn M, Nahnsen S, Hilke FJ, Scheiner B, Dufour JF, De Toni EN, Pinter M, Malek NP, Bitzer M. Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 33353145 DOI: 10.3390/cancers12123830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
157 Ventura-Cots M, Concepción M, Arranz JA, Simón-Talero M, Torrens M, Blanco-Grau A, Fuentes I, Suñé P, Alvarado-Tapias E, Gely C, Roman E, Mínguez B, Soriano G, Genescà J, Córdoba J. Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients. Therap Adv Gastroenterol 2016;9:823-35. [PMID: 27803737 DOI: 10.1177/1756283X16658252] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
158 Bouza E, Alcalá L, Marín M, Valerio M, Reigadas E, Muñoz P, González-del Vecchio M, de Egea V. An outbreak of Clostridium difficile PCR ribotype 027 in Spain: risk factors for recurrence and a novel treatment strategy. Eur J Clin Microbiol Infect Dis 2017;36:1777-86. [DOI: 10.1007/s10096-017-2991-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
159 Riggio O, Nardelli S, Gioia S, Lucidi C, Merli M. Management of hepatic encephalopathy as an inpatient. Clin Liver Dis (Hoboken) 2015;5:79-82. [PMID: 31040956 DOI: 10.1002/cld.457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
160 Pendela VS, Kudaravalli P, Munoz A, Razzouk G. A Mysterious Case of Recurrent Acute Hyperammonemic Encephalopathy. Cureus 2020;12:e7484. [PMID: 32351862 DOI: 10.7759/cureus.7484] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
161 Sharma P, Sharma BC. Management of overt hepatic encephalopathy. J Clin Exp Hepatol 2015;5:S82-7. [PMID: 26041964 DOI: 10.1016/j.jceh.2014.04.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
162 Liu J, Lkhagva E, Chung HJ, Kim HJ, Hong ST. The Pharmabiotic Approach to Treat Hyperammonemia. Nutrients 2018;10:E140. [PMID: 29382084 DOI: 10.3390/nu10020140] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
163 Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146:1513-1524. [PMID: 24440671 DOI: 10.1053/j.gastro.2014.01.020] [Cited by in Crossref: 487] [Cited by in F6Publishing: 468] [Article Influence: 60.9] [Reference Citation Analysis]
164 Saab S, Zhao M, Asokan I, Yum JJ, Lee EW. History of Hepatic Encephalopathy Is Not a Contraindication to Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites. Clin Transl Gastroenterol 2021;12:e00378. [PMID: 34333500 DOI: 10.14309/ctg.0000000000000378] [Reference Citation Analysis]
165 Wright G, Swain M, Annane D, Saliba F, Samuel D, Arroyo V, DeMorrow S, Witt A. Neuroinflammation in liver disease: sessional talks from ISHEN. Metab Brain Dis 2016;31:1339-54. [PMID: 27726053 DOI: 10.1007/s11011-016-9918-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
166 Sopeña F, Lanas A. Management of colonic diverticular disease with poorly absorbed antibiotics and other therapies. Therap Adv Gastroenterol 2011;4:365-74. [PMID: 22043229 DOI: 10.1177/1756283X11412820] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
167 Ren Z, Cui G, Lu H, Chen X, Jiang J, Liu H, He Y, Ding S, Hu Z, Wang W. Liver ischemic preconditioning (IPC) improves intestinal microbiota following liver transplantation in rats through 16s rDNA-based analysis of microbial structure shift. PLoS One. 2013;8:e75950. [PMID: 24098410 DOI: 10.1371/journal.pone.0075950] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
168 Uchida Y, Tsuji S, Uemura H, Kouyama JI, Naiki K, Sugawara K, Nakao M, Inao M, Nakayama N, Imai Y, Tomiya T, Mochida S. Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis. Hepatol Res 2020;50:1264-74. [PMID: 32833292 DOI: 10.1111/hepr.13564] [Reference Citation Analysis]
169 Suraweera D, Sundaram V, Saab S. Evaluation and Management of Hepatic Encephalopathy: Current Status and Future Directions. Gut Liver. 2016;10:509-519. [PMID: 27377741 DOI: 10.5009/gnl15419] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 6.6] [Reference Citation Analysis]
170 Patidar KR, Bajaj JS. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management. Clin Gastroenterol Hepatol 2015;13:2048-61. [PMID: 26164219 DOI: 10.1016/j.cgh.2015.06.039] [Cited by in Crossref: 87] [Cited by in F6Publishing: 65] [Article Influence: 12.4] [Reference Citation Analysis]
171 Kimber C, Zhang S, Johnson C, West RE 3rd, Prokopienko AJ, Mahnken JD, Yu AS, Hoofnagle AN, Ir D, Robertson CE, Miyazaki M, Chonchol M, Jovanovich A, Kestenbaum B, Frank DN, Nolin TD, Stubbs JR. Randomized, Placebo-Controlled Trial of Rifaximin Therapy for Lowering Gut-Derived Cardiovascular Toxins and Inflammation in CKD. Kidney360 2020;1:1206-16. [PMID: 34322673 DOI: 10.34067/kid.0003942020] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
172 Bass NM. A Brief History of Hepatic Encephalopathy. Clin Liver Dis (Hoboken) 2021;18:49-62. [PMID: 34745583 DOI: 10.1002/cld.1119] [Reference Citation Analysis]
173 Bajaj JS, Betrapally NS, Hylemon PB, Thacker LR, Daita K, Kang DJ, White MB, Unser AB, Fagan A, Gavis EA, Sikaroodi M, Dalmet S, Heuman DM, Gillevet PM. Gut Microbiota Alterations can predict Hospitalizations in Cirrhosis Independent of Diabetes Mellitus. Sci Rep. 2015;5:18559. [PMID: 26692421 DOI: 10.1038/srep18559] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
174 Barger M, Blodget E, Pena S, Mack W, Fong TL. VRE in cirrhotic patients. BMC Infect Dis 2019;19:711. [PMID: 31409282 DOI: 10.1186/s12879-019-4352-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
175 Liu A, Perumpail RB, Kumari R, Younossi ZM, Wong RJ, Ahmed A. Advances in cirrhosis: Optimizing the management of hepatic encephalopathy. World J Hepatol 2015; 7(29): 2871-2879 [PMID: 26692331 DOI: 10.4254/wjh.v7.i29.2871] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
176 Suk KT, Baik SK, Yoon JH, Cheong JY, Paik YH, Lee CH, Kim YS, Lee JW, Kim DJ, Cho SW, Hwang SG, Sohn JH, Kim MY, Kim YB, Kim JG, Cho YK, Choi MS, Kim HJ, Lee HW, Kim SU, Kim JK, Choi JY, Jun DW, Tak WY, Lee BS, Jang BK, Chung WJ, Kim HS, Jang JY, Jeong SW, Kim SG, Kwon OS, Jung YK, Choe WH, Lee JS, Kim IH, Shim JJ, Cheon GJ, Bae SH, Seo YS, Choi DH, Jang SJ; Korean Association for the Study of the Liver. Revision and update on clinical practice guideline for liver cirrhosis. Korean J Hepatol. 2012;18:1-21. [PMID: 22511898 DOI: 10.3350/kjhep.2012.18.1.1] [Cited by in Crossref: 94] [Cited by in F6Publishing: 87] [Article Influence: 9.4] [Reference Citation Analysis]
177 Phongsamran PV, Kim JW, Cupo Abbott J, Rosenblatt A. Pharmacotherapy for Hepatic Encephalopathy: . Drugs 2010;70:1131-48. [DOI: 10.2165/10898630-000000000-00000] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
178 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Reference Citation Analysis]
179 Gupta T, Rathi S, K Dhiman R. Managing Encephalopathy in the Outpatient Setting. Euroasian J Hepatogastroenterol 2017;7:48-54. [PMID: 29201772 DOI: 10.5005/jp-journals-10018-1211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
180 Javaid N, Choi S. Toll-like Receptors from the Perspective of Cancer Treatment. Cancers (Basel) 2020;12:E297. [PMID: 32012718 DOI: 10.3390/cancers12020297] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
181 Malaguarnera G, Giordano M, Nunnari G, Bertino G, Malaguarnera M. Gut microbiota in alcoholic liver disease: Pathogenetic role and therapeutic perspectives. World J Gastroenterol 2014; 20(44): 16639-16648 [PMID: 25469033 DOI: 10.3748/wjg.v20.i44.16639] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 67] [Article Influence: 9.4] [Reference Citation Analysis]
182 Huang JS, Jiang ZD, Garey KW, Lasco T, Dupont HL. Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile. Antimicrob Agents Chemother. 2013;57:2690-2693. [PMID: 23545528 DOI: 10.1128/aac.00548-13] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
183 Koo HL, Sabounchi S, Huang DB, DuPont HL. Rifaximin therapy of irritable bowel syndrome. Clin Med Insights Gastroenterol 2012;5:31-41. [PMID: 24833932 DOI: 10.4137/CGast.S7382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
184 Vidot H, Cvejic E, Finegan LJ, Shores EA, Bowen DG, Strasser SI, McCaughan GW, Carey S, Allman-Farinelli M, Shackel NA. Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study. Nutrients 2019;11:E1810. [PMID: 31390762 DOI: 10.3390/nu11081810] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
185 Frenette CT, Levy C, Saab S. Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door. Dig Dis Sci 2021. [PMID: 34169435 DOI: 10.1007/s10620-021-07075-2] [Reference Citation Analysis]
186 Ishikawa T, Endo S, Imai M, Azumi M, Nozawa Y, Sano T, Iwanaga A, Honma T, Yoshida T. Changes in the Body Composition and Nutritional Status after Long-term Rifaximin Therapy for Hyperammonemia in Japanese Patients with Hepatic Encephalopathy. Intern Med 2020;59:2465-9. [PMID: 33055469 DOI: 10.2169/internalmedicine.5094-20] [Reference Citation Analysis]
187 Teperman LW. Impact of pretransplant hepatic encephalopathy on liver posttransplantation outcomes. Int J Hepatol 2013;2013:952828. [PMID: 24324895 DOI: 10.1155/2013/952828] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
188 Luo M, Guo JY, Cao WK. Inflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosis. World J Gastroenterol 2015; 21(41): 11815-11824 [PMID: 26557005 DOI: 10.3748/wjg.v21.i41.11815] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
189 Frontera JA. Management of hepatic encephalopathy. Curr Treat Options Neurol. 2014;16:297. [PMID: 24807164 DOI: 10.1007/s11940-014-0297-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
190 Bajaj JS, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011;140:478-487.e1. [PMID: 20849805 DOI: 10.1053/j.gastro.2010.08.061] [Cited by in Crossref: 141] [Cited by in F6Publishing: 125] [Article Influence: 11.8] [Reference Citation Analysis]
191 Rothstein DM. Rifamycins, Alone and in Combination. Cold Spring Harb Perspect Med 2016;6:a027011. [PMID: 27270559 DOI: 10.1101/cshperspect.a027011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 5.7] [Reference Citation Analysis]
192 Bai Z, Bernardi M, Yoshida EM, Li H, Guo X, Méndez-Sánchez N, Li Y, Wang R, Deng J, Qi X. Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis. Aging (Albany NY) 2019;11:8502-25. [PMID: 31596729 DOI: 10.18632/aging.102335] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
193 Tapper EB, Asrani SK. The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. J Hepatol. 2020;73:441-445. [PMID: 32298769 DOI: 10.1016/j.jhep.2020.04.005] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 35.0] [Reference Citation Analysis]
194 Bajaj JS, Tandon P, OʼLeary JG, Wong F, Biggins SW, Garcia-Tsao G, Kamath PS, Maliakkal B, Fallon MB, Lai JC, Thuluvath PJ, Vargas HE, Subramanian RM, Thacker LR, Reddy KR. Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. Am J Gastroenterol 2019;114:599-606. [PMID: 30694868 DOI: 10.14309/ajg.0000000000000044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
195 Bruetto RG, Rodrigues FB, Torres US, Otaviano AP, Zanetta DM, Burdmann EA. Renal function at hospital admission and mortality due to acute kidney injury after myocardial infarction. PLoS One. 2012;7:e35496. [PMID: 22539974 DOI: 10.1371/journal.pone] [Cited by in F6Publishing: 90] [Reference Citation Analysis]
196 Upadhyay R, Bleck TP, Busl KM. Hyperammonemia: What Urea-lly Need to Know: Case Report of Severe Noncirrhotic Hyperammonemic Encephalopathy and Review of the Literature. Case Rep Med 2016;2016:8512721. [PMID: 27738433 DOI: 10.1155/2016/8512721] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 3.7] [Reference Citation Analysis]
197 Acharya C, Bajaj JS. Altered Microbiome in Patients With Cirrhosis and Complications. Clin Gastroenterol Hepatol 2019;17:307-21. [PMID: 30099098 DOI: 10.1016/j.cgh.2018.08.008] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 11.5] [Reference Citation Analysis]
198 Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, Shibuya A, Seike M, Nagoshi S, Segawa M, Tsubouchi H, Moriwaki H, Kato A, Hashimoto E, Michitaka K, Murawaki T, Sugano K, Watanabe M, Shimosegawa T. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol 2016;51:629-50. [PMID: 27246107 DOI: 10.1007/s00535-016-1216-y] [Cited by in Crossref: 181] [Cited by in F6Publishing: 163] [Article Influence: 30.2] [Reference Citation Analysis]
199 Ruiz-Patiño A, Barrón F, Cardona AF, Corrales L, Mas L, Martín C, Zatarain-Barrón ZL, Recondo G, Ricaurte L, Rojas L, Archila P, Rodríguez J, Sotelo C, Viola L, Vargas C, Carranza H, Otero J, Pino LE, Rolfo C, Rosell R, Arrieta O; CLICaP. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP). Thorac Cancer 2020;11:2552-60. [PMID: 32705787 DOI: 10.1111/1759-7714.13573] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
200 Chandna S, Zarate ER, Gallegos-Orozco JF. Management of Decompensated Cirrhosis and Associated Syndromes. Surg Clin North Am 2022;102:117-37. [PMID: 34800381 DOI: 10.1016/j.suc.2021.09.005] [Reference Citation Analysis]
201 Shen TC, Albenberg L, Bittinger K, Chehoud C, Chen YY, Judge CA, Chau L, Ni J, Sheng M, Lin A. Engineering the gut microbiota to treat hyperammonemia. J Clin Invest. 2015;125:2841-2850. [PMID: 26098218 DOI: 10.1172/jci79214] [Cited by in Crossref: 103] [Cited by in F6Publishing: 59] [Article Influence: 14.7] [Reference Citation Analysis]
202 Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol 2017;14:527-39. [PMID: 28676707 DOI: 10.1038/nrgastro.2017.72] [Cited by in Crossref: 176] [Cited by in F6Publishing: 168] [Article Influence: 35.2] [Reference Citation Analysis]
203 Patidar KR, Thacker LR, Wade JB, Sterling RK, Sanyal AJ, Siddiqui MS, Matherly SC, Stravitz RT, Puri P, Luketic VA, Fuchs M, White MB, Noble NA, Unser AB, Gilles H, Heuman DM, Bajaj JS. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization. Am J Gastroenterol. 2014;109:1757-1763. [PMID: 25178701 DOI: 10.1038/ajg.2014.264] [Cited by in Crossref: 99] [Cited by in F6Publishing: 79] [Article Influence: 12.4] [Reference Citation Analysis]
204 Minuk GY, Hawkins K, Kaita KD, Wong S, Renner E, Minuk L, Uhanova J. Daily ciprofloxacin treatment for patients with advanced liver disease awaiting liver transplantation reduces hospitalizations. Dig Dis Sci 2011;56:1235-41. [PMID: 21057977 DOI: 10.1007/s10620-010-1456-2] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
205 Tiberi O, Tognarelli JM, Cook NA, Crossey MM, Dhanjal NS, Taylor-Robinson SD. Diagnosing and treating hepatic encephalopathy. Br J Hosp Med (Lond) 2015;76:646, 648-52, 654. [PMID: 26551495 DOI: 10.12968/hmed.2015.76.11.646] [Reference Citation Analysis]
206 Chi ZC. Intestinal barrier dysfunction and alcoholic liver disease. Shijie Huaren Xiaohua Zazhi 2019; 27(19): 1179-1192 [DOI: 10.11569/wcjd.v27.i19.1179] [Reference Citation Analysis]
207 Tranah TH, Kronsten VT, Shawcross DL. Implications and Management of Cirrhosis-Associated Immune Dysfunction Before and After Liver Transplantation. Liver Transpl 2021. [PMID: 34738724 DOI: 10.1002/lt.26353] [Reference Citation Analysis]
208 Kim TY, Kim DJ. Acute-on-chronic liver failure. Clin Mol Hepatol. 2013;19:349-359. [PMID: 24459638 DOI: 10.3350/cmh.2013.19.4.349] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 4.8] [Reference Citation Analysis]
209 Ventura-Cots M, Simón-Talero M, Poca M, Ariza X, Masnou H, Sanchez J, Llop E, Cañete N, Martín-Llahí M, Amador A, Martínez J, Clemente-Sanchez A, Puente A, Torrens M, Alvarado-Tapias E, Napoleone L, Miquel-Planas M, Ardèvol A, Casas Rodrigo M, Calleja JL, Solé C, Soriano G, Genescà J. Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. J Clin Med 2021;10:4885. [PMID: 34768404 DOI: 10.3390/jcm10214885] [Reference Citation Analysis]
210 Cordoba J. Hepatic Encephalopathy: From the Pathogenesis to the New Treatments. ISRN Hepatol 2014;2014:236268. [PMID: 27335836 DOI: 10.1155/2014/236268] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
211 Hadjihambi A, Arias N, Sheikh M, Jalan R. Hepatic encephalopathy a critical current review. Hepatol Int. 2018;12:135-147. [PMID: 28770516 DOI: 10.1007/s12072-017-9812-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 11.6] [Reference Citation Analysis]
212 Krajina A, Hulek P, Fejfar T, Valek V. Quality improvement guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS). Cardiovasc Intervent Radiol. 2012;35:1295-1300. [PMID: 23070105 DOI: 10.1007/s00270-012-0493] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
213 Fritz CD, Adebajo C, Aronsohn A, Jensen DM. A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy. ACG Case Rep J 2014;2:42-4. [PMID: 26157902 DOI: 10.14309/crj.2014.79] [Reference Citation Analysis]
214 Schoenfeld P, Pimentel M, Chang L, Lembo A, Chey WD, Yu J, Paterson C, Bortey E, Forbes WP. Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39:1161-1168. [PMID: 24697851 DOI: 10.1111/apt.12735] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 7.1] [Reference Citation Analysis]
215 Mangini C, Montagnese S. New Therapies of Liver Diseases: Hepatic Encephalopathy. J Clin Med 2021;10:4050. [PMID: 34575157 DOI: 10.3390/jcm10184050] [Reference Citation Analysis]
216 Bernardi M, Ricci CS, Zaccherini G. Role of human albumin in the management of complications of liver cirrhosis. J Clin Exp Hepatol 2014;4:302-11. [PMID: 25755577 DOI: 10.1016/j.jceh.2014.08.007] [Cited by in Crossref: 56] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
217 Wittenburg H, Tennert U, Berg T. [Complications of liver cirrhosis]. Internist (Berl). 2011;52:1061-170; quiz 1061-170;. [PMID: 21611819 DOI: 10.1007/s00108-011-2853-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
218 Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2010;7:515-25. [DOI: 10.1038/nrgastro.2010.116] [Cited by in Crossref: 174] [Cited by in F6Publishing: 152] [Article Influence: 14.5] [Reference Citation Analysis]
219 Sharma BC, Maharshi S. Prevention of hepatic encephalopathy recurrence. Clin Liver Dis (Hoboken) 2015;5:64-7. [PMID: 31040952 DOI: 10.1002/cld.446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
220 Bajaj JS, Cordoba J, Mullen KD, Amodio P, Shawcross DL, Butterworth RF, Morgan MY; International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). Review article: the design of clinical trials in hepatic encephalopathy--an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther. 2011;33:739-747. [PMID: 21306407 DOI: 10.1111/j.1365-2036.2011.04590.x] [Cited by in Crossref: 216] [Cited by in F6Publishing: 182] [Article Influence: 19.6] [Reference Citation Analysis]
221 Tapper EB, Parikh ND, Green PK, Berry K, Waljee AK, Moon AM, Ioannou GN. Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection. Clin Gastroenterol Hepatol 2020;18:1197-1206.e7. [PMID: 31589975 DOI: 10.1016/j.cgh.2019.09.033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
222 Higuera-de-la-Tijera F, Servín-Caamaño AI, Salas-Gordillo F, Pérez-Hernández JL, Abdo-Francis JM, Camacho-Aguilera J, Alla SN, Jiménez-Ponce F. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding. Can J Gastroenterol Hepatol 2018;2018:3015891. [PMID: 30079329 DOI: 10.1155/2018/3015891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
223 Moreno-Gonzalez M, Beraza N. The Role of the Microbiome in Liver Cancer. Cancers (Basel) 2021;13:2330. [PMID: 34066064 DOI: 10.3390/cancers13102330] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
224 Chassaing B, Etienne-Mesmin L, Gewirtz AT. Microbiota-liver axis in hepatic disease. Hepatology 2014;59:328-39. [PMID: 23703735 DOI: 10.1002/hep.26494] [Cited by in Crossref: 181] [Cited by in F6Publishing: 183] [Article Influence: 20.1] [Reference Citation Analysis]
225 Kimer N, Krag A, Gluud LL. Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy. Patient Prefer Adherence. 2014;8:331-338. [PMID: 24672227 DOI: 10.2147/PPA.S41565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
226 Harputluoglu MM, Demirel U, Gul M, Temel I, Gursoy S, Selcuk EB, Aladag M, Bilgic Y, Gunduz E, Seckin Y. Effects of rifaximin on bacterial translocation in thioacetamide-induced liver injury in rats. Inflammation 2012;35:1512-7. [PMID: 22527146 DOI: 10.1007/s10753-012-9465-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
227 Flatt E, McLin VA, Braissant O, Pierzchala K, Mastromarino P, Mitrea SO, Sessa D, Gruetter R, Cudalbu C. Probiotics combined with rifaximin influence the neurometabolic changes in a rat model of type C HE. Sci Rep 2021;11:17988. [PMID: 34504135 DOI: 10.1038/s41598-021-97018-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
228 Elzubeir A, Alam SM. Letter to editor ‘prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with Rifaxamin’. World J Gastroenterol 2020; 26(44): 7085-7087 [PMID: 33311952 DOI: 10.3748/wjg.v26.i44.7085] [Reference Citation Analysis]
229 Bittinger M, Messmann H. [Chronic critically ill patients from a gastroenterological perspective]. Med Klin Intensivmed Notfmed 2013;108:285-9. [PMID: 23423578 DOI: 10.1007/s00063-012-0195-x] [Reference Citation Analysis]
230 Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011;141:1572-1585. [PMID: 21920463 DOI: 10.1053/j.gastro.2011.09.002] [Cited by in Crossref: 1046] [Cited by in F6Publishing: 1007] [Article Influence: 95.1] [Reference Citation Analysis]
231 Ponziani FR, Gerardi V, Pecere S, D’Aversa F, Lopetuso L, Zocco MA, Pompili M, Gasbarrini A. Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. World J Gastroenterol 2015; 21(43): 12322-12333 [PMID: 26604640 DOI: 10.3748/wjg.v21.i43.12322] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 34] [Article Influence: 5.3] [Reference Citation Analysis]
232 Hu H, Lin A, Kong M, Yao X, Yin M, Xia H, Ma J, Liu H. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol 2020;55:142-58. [PMID: 31845054 DOI: 10.1007/s00535-019-01649-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
233 Krajina A, Hulek P, Fejfar T, Valek V. Quality improvement guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS). Cardiovasc Intervent Radiol. 2012;35:1295-1300. [PMID: 23070105 DOI: 10.1007/s00270-012-0493-y] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
234 Tamai Y, Iwasa M, Eguchi A, Shigefuku R, Kamada Y, Miyoshi E, Takei Y. Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy. JGH Open 2021;5:827-30. [PMID: 34263080 DOI: 10.1002/jgh3.12596] [Reference Citation Analysis]
235 Patel VC, White H, Støy S, Bajaj JS, Shawcross DL. Clinical science workshop: targeting the gut-liver-brain axis. Metab Brain Dis 2016;31:1327-37. [PMID: 26446022 DOI: 10.1007/s11011-015-9743-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
236 Qin N, Yang F, Li A, Prifti E, Chen Y, Shao L, Guo J, Le Chatelier E, Yao J, Wu L, Zhou J, Ni S, Liu L, Pons N, Batto JM, Kennedy SP, Leonard P, Yuan C, Ding W, Chen Y, Hu X, Zheng B, Qian G, Xu W, Ehrlich SD, Zheng S, Li L. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513:59-64. [PMID: 25079328 DOI: 10.1038/nature13568] [Cited by in Crossref: 980] [Cited by in F6Publishing: 893] [Article Influence: 122.5] [Reference Citation Analysis]
237 Han X, Luo Z, Wang W, Zheng P, Li T, Mei Z, Wang J. Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy. Front Pharmacol 2021;12:696065. [PMID: 34690751 DOI: 10.3389/fphar.2021.696065] [Reference Citation Analysis]
238 Olson JC. Intensive Care Management of Patients with Cirrhosis. Curr Treat Options Gastroenterol 2018;16:241-52. [PMID: 29616404 DOI: 10.1007/s11938-018-0182-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
239 Komolafe O, Roberts D, Freeman SC, Wilson P, Sutton AJ, Cooper NJ, Pavlov CS, Milne EJ, Hawkins N, Cowlin M, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 2020;1:CD013125. [PMID: 31978256 DOI: 10.1002/14651858.CD013125.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
240 Lutz P, Nischalke HD, Strassburg CP, Spengler U. Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver. World J Hepatol 2015; 7(3): 304-314 [PMID: 25848460 DOI: 10.4254/wjh.v7.i3.304] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
241 Dalal R, McGee RG, Riordan SM, Webster AC. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2:CD008716. [PMID: 28230908 DOI: 10.1002/14651858.cd008716.pub3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
242 Ventura-Cots M, Carmona I, Moreno C, Ampuero J, Simón-Talero M, Sanpedro F, Les I, Romero-Gómez M, Genescà J. Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. Therap Adv Gastroenterol 2018;11:1756283X17743419. [PMID: 29383024 DOI: 10.1177/1756283X17743419] [Cited by in Crossref: 7] [Article Influence: 1.4] [Reference Citation Analysis]
243 Sinkala E, Zyambo K, Besa E, Kaonga P, Nsokolo B, Kayamba V, Vinikoor M, Zulu R, Bwalya M, Foster GR, Kelly P. Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial. Am J Trop Med Hyg 2018;98:1152-8. [PMID: 29436337 DOI: 10.4269/ajtmh.17-0637] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
244 de Jong LA, van Schoonhoven AV, Hofstra HS, Postma MJ, van Hoek B. Budget impact of optimizing rifaximin-α use for the prevention of recurrent hepatic encephalopathy in The Netherlands. J Med Econ 2021;24:1149-63. [PMID: 34629016 DOI: 10.1080/13696998.2021.1983291] [Reference Citation Analysis]
245 Leise MD, Poterucha JJ, Kamath PS, Kim WR. Management of hepatic encephalopathy in the hospital. Mayo Clin Proc 2014;89:241-53. [PMID: 24411831 DOI: 10.1016/j.mayocp.2013.11.009] [Cited by in Crossref: 64] [Cited by in F6Publishing: 46] [Article Influence: 8.0] [Reference Citation Analysis]
246 Kang DJ, Kakiyama G, Betrapally NS, Herzog J, Nittono H, Hylemon PB, Zhou H, Carroll I, Yang J, Gillevet PM, Jiao C, Takei H, Pandak WM, Iida T, Heuman DM, Fan S, Fiehn O, Kurosawa T, Sikaroodi M, Sartor RB, Bajaj JS. Rifaximin Exerts Beneficial Effects Independent of its Ability to Alter Microbiota Composition. Clin Transl Gastroenterol 2016;7:e187. [PMID: 27560928 DOI: 10.1038/ctg.2016.44] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
247 Ito T, Nakamura K, Kageyama S, Korayem IM, Hirao H, Kadono K, Aziz J, Younan S, DiNorcia J 3rd, Agopian VG, Yersiz H, Farmer DG, Busuttil RW, Kupiec-Weglinski JW, Kaldas FM. Impact of Rifaximin Therapy on Ischemia/Reperfusion Injury in Liver Transplantation: A Propensity Score-Matched Analysis. Liver Transpl 2019;25:1778-89. [PMID: 31509643 DOI: 10.1002/lt.25633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
248 Lutz P, Parcina M, Bekeredjian-Ding I, Nischalke HD, Nattermann J, Sauerbruch T, Hoerauf A, Strassburg CP, Spengler U. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLoS One. 2014;9:e93909. [PMID: 24714550 DOI: 10.1371/journal.pone.0093909] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
249 Pimentel M, Cash BD, Lembo A, Wolf RA, Israel RJ, Schoenfeld P. Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity. Dig Dis Sci 2017;62:2455-63. [PMID: 28589238 DOI: 10.1007/s10620-017-4598-7] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 4.6] [Reference Citation Analysis]
250 Chapuy CI, Sahai I, Sharma R, Zhu AX, Kozyreva ON. Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm. Oncologist 2016;21:514-20. [PMID: 26975868 DOI: 10.1634/theoncologist.2015-0267] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
251 Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K. Evidence-based clinical practice guidelines for Liver Cirrhosis 2020. J Gastroenterol 2021;56:593-619. [PMID: 34231046 DOI: 10.1007/s00535-021-01788-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
252 Kronsten VT, Tranah TH, Pariante C, Shawcross DL. Gut-derived systemic inflammation as a driver of depression in chronic liver disease. J Hepatol 2021:S0168-8278(21)02180-2. [PMID: 34800610 DOI: 10.1016/j.jhep.2021.11.008] [Reference Citation Analysis]
253 Sawhney R, Jalan R. Liver: the gut is a key target of therapy in hepatic encephalopathy. Nat Rev Gastroenterol Hepatol 2015;12:7-8. [PMID: 25348849 DOI: 10.1038/nrgastro.2014.185] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
254 Ferenci P. Hepatic encephalopathy. Gastroenterol Rep (Oxf). 2017;5:138-147. [PMID: 28533911 DOI: 10.1093/gastro/gox013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
255 Soyano AE, Reynolds G, Moreno-Aspitia A, Chumsri S. Rifaximin for Pertuzumab-Related GI Toxicities. Front Oncol 2017;7:168. [PMID: 28848707 DOI: 10.3389/fonc.2017.00168] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
256 Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol 2015;1:275-84. [PMID: 26090511 DOI: 10.1016/j.jcmgh.2015.04.003] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 13.3] [Reference Citation Analysis]
257 Giannelli V, Di Gregorio V, Iebba V, Giusto M, Schippa S, Merli M, Thalheimer U. Microbiota and the gut-liver axis: Bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol 2014; 20(45): 16795-16810 [PMID: 25492994 DOI: 10.3748/wjg.v20.i45.16795] [Cited by in CrossRef: 123] [Cited by in F6Publishing: 104] [Article Influence: 15.4] [Reference Citation Analysis]
258 Italian Association for the Study of the Liver (AISF). Portal Hypertension and Ascites: Patient-and Population-centered Clinical Practice Guidelines by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2021;53:1089-104. [PMID: 34321192 DOI: 10.1016/j.dld.2021.06.021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
259 Seyan AS, Hughes RD, Shawcross DL. Changing face of hepatic encephalopathy: Role of inflammation and oxidative stress. World J Gastroenterol 2010; 16(27): 3347-3357 [PMID: 20632436 DOI: 10.3748/wjg.v16.i27.3347] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 62] [Article Influence: 5.9] [Reference Citation Analysis]
260 Brahmania M, Renner EL, Coffin CS, Yoshida EM, Wong P, Zeman M, Shah H. Choosing Wisely Canada-Top Five List in Hepatology: Official Position Statement of the Canadian Association for the Study of the Liver (CASL) and Choosing Wisely Canada (CWC). Annals of Hepatology 2019;18:165-71. [DOI: 10.5604/01.3001.0012.7908] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
261 Huang YW, Yang SS, Kao JH. Pathogenesis and management of alcoholic liver cirrhosis: a review. Hepat Med 2011;3:1-11. [PMID: 24367215 DOI: 10.2147/HMER.S10265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
262 Berzigotti A. Advances and challenges in cirrhosis and portal hypertension. BMC Med. 2017;15:200. [PMID: 29121925 DOI: 10.1186/s12916-017-0966-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 5.4] [Reference Citation Analysis]
263 Kaji K, Takaya H, Saikawa S, Furukawa M, Sato S, Kawaratani H, Kitade M, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity. World J Gastroenterol 2017; 23(47): 8355-8366 [PMID: 29307995 DOI: 10.3748/wjg.v23.i47.8355] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 31] [Article Influence: 8.0] [Reference Citation Analysis]
264 Ye JF, Ju J. Rifaximin for prevention and treatment of hepatic encephalopathy. Shijie Huaren Xiaohua Zazhi 2015; 23(7): 1090-1096 [DOI: 10.11569/wcjd.v23.i7.1090] [Reference Citation Analysis]
265 Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. Cochrane Database Syst Rev. 2018;5:CD012410. [PMID: 29762873 DOI: 10.1002/14651858.cd012410.pub2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
266 Nishida S, Hamada K, Nishino N, Fukushima D, Koyanagi R, Horikawa Y, Shiwa Y, Saitoh S. Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese. World J Hepatol 2019; 11(6): 531-541 [PMID: 31293721 DOI: 10.4254/wjh.v11.i6.531] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
267 China L, Skene SS, Shabir Z, Maini A, Sylvestre Y, Bennett K, Bevan S, O'Beirne J, Forrest E, Portal J, Ryder S, Wright G, Gilroy DW, O'Brien A. Administration of Albumin Solution Increases Serum Levels of Albumin in Patients With Chronic Liver Failure in a Single-Arm Feasibility Trial. Clin Gastroenterol Hepatol 2018;16:748-755.e6. [PMID: 28911947 DOI: 10.1016/j.cgh.2017.09.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
268 Bajaj JS, O'Leary JG, Wong F, Reddy KR, Kamath PS. Bacterial infections in end-stage liver disease: current challenges and future directions. Gut. 2012;61:1219-1225. [PMID: 22661495 DOI: 10.1136/gutjnl-2012-302339] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 5.5] [Reference Citation Analysis]
269 Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis 2013;28:307-12. [PMID: 23389621 DOI: 10.1007/s11011-013-9383-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
270 Bajaj JS, Barrett AC, Bortey E, Paterson C, Forbes WP. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis. Aliment Pharmacol Ther. 2015;41:39-45. [PMID: 25339518 DOI: 10.1111/apt.12993] [Cited by in Crossref: 38] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
271 Ryu AJ, Rahimi RS, Leise MD. The Current Hepatic Encephalopathy Pipeline. J Clin Exp Hepatol 2020;10:377-85. [PMID: 32655239 DOI: 10.1016/j.jceh.2020.01.001] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
272 Malach M, Baumol WJ. Opportunities for cost reduction of medical care: part 3. J Community Health 2012;37:888-96. [PMID: 22258633 DOI: 10.1007/s10900-011-9534-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
273 Salehi S, Tranah TH, Lim S, Heaton N, Heneghan M, Aluvihare V, Patel VC, Shawcross DL. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. Aliment Pharmacol Ther 2019;50:435-41. [PMID: 31169941 DOI: 10.1111/apt.15326] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
274 Krag A, Schuchmann M, Sodatonou H, Pilot J, Whitehouse J, Strasser SI, Hudson M. Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients' Experience on Rifaximin-α (PROSPER): an observational study among 550 patients. Hepatol Med Policy 2018;3:4. [PMID: 30288327 DOI: 10.1186/s41124-017-0029-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
275 Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, Caviglia JM, Khiabanian H, Adeyemi A, Bataller R, Lefkowitch JH, Bower M, Friedman R, Sartor RB, Rabadan R, Schwabe RF. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012;21:504-16. [PMID: 22516259 DOI: 10.1016/j.ccr.2012.02.007] [Cited by in Crossref: 637] [Cited by in F6Publishing: 613] [Article Influence: 63.7] [Reference Citation Analysis]
276 Krishnarao A, Gordon FD. Prognosis of Hepatic Encephalopathy. Clin Liver Dis 2020;24:219-29. [PMID: 32245529 DOI: 10.1016/j.cld.2020.01.004] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
277 Sidhu GS, Go A, Attar BM, Mutneja HR, Arora S, Patel SA. Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review. BMJ Open Gastroenterol. 2017;4:e000154. [PMID: 28944070 DOI: 10.1136/bmjgast-2017-000154] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
278 Lerschmacher O, Koch A, Streetz K, Trautwein C, Tacke F. [Management of decompensated liver cirrhosis in the intensive care unit]. Med Klin Intensivmed Notfmed. 2013;108:646-656. [PMID: 24030843 DOI: 10.1007/s00063-013-0259-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
279 Hsu DC, Sereti I. Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection. Drugs 2016;76:533-49. [PMID: 26915027 DOI: 10.1007/s40265-016-0546-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
280 de Wit K, Schaapman JJ, Nevens F, Verbeek J, Coenen S, Cuperus FJC, Kramer M, Tjwa ETTL, Mostafavi N, Dijkgraaf MGW, van Delden OM, Beuers UHW, Coenraad MJ, Takkenberg RB. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial). BMJ Open Gastroenterol 2020;7:e000531. [PMID: 33372103 DOI: 10.1136/bmjgast-2020-000531] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
281 Bohra A, Worland T, Hui S, Terbah R, Farrell A, Robertson M. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care. World J Gastroenterol 2020; 26(18): 2221-2231 [PMID: 32476788 DOI: 10.3748/wjg.v26.i18.2221] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
282 Nakamura K, Kageyama S, Ito T, Hirao H, Kadono K, Aziz A, Dery KJ, Everly MJ, Taura K, Uemoto S, Farmer DG, Kaldas FM, Busuttil RW, Kupiec-Weglinski JW. Antibiotic pretreatment alleviates liver transplant damage in mice and humans. J Clin Invest 2019;129:3420-34. [PMID: 31329160 DOI: 10.1172/JCI127550] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
283 Garcovich M, Zocco MA, Roccarina D, Ponziani FR, Gasbarrini A. Prevention and treatment of hepatic encephalopathy: Focusing on gut microbiota. World J Gastroenterol 2012; 18(46): 6693-6700 [PMID: 23239905 DOI: 10.3748/wjg.v18.i46.6693] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
284 Buldain D, Gortari Castillo L, Buchamer AV, Aliverti F, Bandoni A, Marchetti L, Mestorino N. Melaleuca armillaris Essential Oil in Combination With Rifaximin Against Staphylococcus aureus Isolated of Dairy Cows. Front Vet Sci 2020;7:344. [PMID: 32760742 DOI: 10.3389/fvets.2020.00344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
285 Kim HY, Kim CW, Choi JY, Lee CD, Lee SH, Kim MY, Jang BK, Wo HY. Complications Requiring Hospital Admission and Causes of In-Hospital Death over Time in Alcoholic and Nonalcoholic Cirrhosis Patients. Gut Liver 2016;10:95-100. [PMID: 26087788 DOI: 10.5009/gnl14363] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
286 Tapper EB, Volk M. Strategies to Reduce 30-Day Readmissions in Patients with Cirrhosis. Curr Gastroenterol Rep 2017;19:1. [PMID: 28101791 DOI: 10.1007/s11894-017-0543-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
287 Iadevaia MD, Prete AD, Cesaro C, Gaeta L, Zulli C, Loguercio C. Rifaximin in the treatment of hepatic encephalopathy. Hepat Med. 2011;3:109-117. [PMID: 24367227 DOI: 10.2147/hmer.s11988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
288 Liu R, Kang JD, Sartor RB, Sikaroodi M, Fagan A, Gavis EA, Zhou H, Hylemon PB, Herzog JW, Li X, Lippman RH, Gonzalez-Maeso J, Wade JB, Ghosh S, Gurley E, Gillevet PM, Bajaj JS. Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant. Hepatology 2020;71:611-26. [PMID: 31220352 DOI: 10.1002/hep.30827] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
289 Bian J, Wang A, Lin J, Wu L, Huang H, Wang S, Yang X, Lu X, Xu Y, Zhao H. Association between proton pump inhibitors and hepatic encephalopathy: A meta-analysis. Medicine (Baltimore) 2017;96:e6723. [PMID: 28445288 DOI: 10.1097/MD.0000000000006723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
290 Sharma P, Sharma BC. Disaccharides in the treatment of hepatic encephalopathy. Metab Brain Dis 2013;28:313-20. [PMID: 23456517 DOI: 10.1007/s11011-013-9392-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
291 Tapper EB, Hao S, Lin M, Mafi JN, McCurdy H, Parikh ND, Lok AS. The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers. Hepatology 2020;71:225-34. [PMID: 31063262 DOI: 10.1002/hep.30695] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
292 Amodio P, Montagnese S, Mullen K, Orr JG, Vilstrup H. Where are we going? Translational research in hepatic encephalopathy. Metab Brain Dis 2016;31:1231-7. [PMID: 26350697 DOI: 10.1007/s11011-015-9728-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
293 Hasan LZ, Wu GY. Novel Agents in the Management of Hepatic Encephalopathy: A Review. J Clin Transl Hepatol 2021;9:749-59. [PMID: 34722190 DOI: 10.14218/JCTH.2021.00102] [Reference Citation Analysis]
294 Bajaj JS, Shamsaddini A, Fagan A, McGeorge S, Gavis E, Sikaroodi M, Brenner LA, Wade JB, Gillevet PM. Distinct gut microbial compositional and functional changes associated with impaired inhibitory control in patients with cirrhosis. Gut Microbes 2021;13:1953247. [PMID: 34346283 DOI: 10.1080/19490976.2021.1953247] [Reference Citation Analysis]
295 Tranah TH, Vijay GK, Ryan JM, Shawcross DL. Systemic inflammation and ammonia in hepatic encephalopathy. Metab Brain Dis. 2013;28:1-5. [PMID: 23224356 DOI: 10.1007/s11011-012-9370-2] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
296 Saboo K, Shamsaddini A, Iyer MV, Hu C, Fagan A, Gavis EA, White MB, Fuchs M, Heuman DM, Sikaroodi M, Iyer RK, Gillevet PM, Bajaj JS. Sex is associated with differences in gut microbial composition and function in hepatic encephalopathy. J Hepatol 2021;74:80-8. [PMID: 32679299 DOI: 10.1016/j.jhep.2020.06.046] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
297 Tapper EB, Finkelstein D, Mittleman MA, Piatkowski G, Chang M, Lai M. A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis. Clin Gastroenterol Hepatol. 2016;14:753-759. [PMID: 26407750 DOI: 10.1016/j.cgh.2015.08.041] [Cited by in Crossref: 82] [Cited by in F6Publishing: 70] [Article Influence: 11.7] [Reference Citation Analysis]
298 Flamm SL. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. Therap Adv Gastroenterol. 2011;4:199-206. [PMID: 21694804 DOI: 10.1177/1756283X11401774] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
299 Zuo Z, Fan H, Tang XD, Chen YM, Xun LT, Li Y, Song ZJ, Zhai HQ. Effect of different treatments and alcohol addiction on gut microbiota in minimal hepatic encephalopathy patients. Exp Ther Med 2017;14:4887-95. [PMID: 29201193 DOI: 10.3892/etm.2017.5141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]